SIGMOID Enters Into a Licence Agreement with Pendopharm for Commercialisation Rights to CyCol in Canada

Sigmoid Pharma and Pendopharm have entered into agreements concerning a licence for exclusive rights to commercialise CyCol in the Canadian market and an equity investment in Sigmoid.

Under the licence agreement, Sigmoid has received an upfront payment and will be eligible for future milestone payments in addition to significant double-digit, tiered royalties on net sales in Canada. Pursuant to the licence agreement, Pendopharm has invested EUR 5 million in Sigmoid at a premium to the most recent fundraising in 2014. The investment will support the advancement of CyCol into Phase III clinical trials; mainly the scale up of Sigmoid’s manufacturing process for CyCol and the underlying SmPill drug delivery technology. David Goodman, CEO of Pharmascience Inc. will join the Sigmoid board of directors.

Dr Ivan S. Coulter, CEO and Founder of Sigmoid, commented: “We are delighted to enter into this important collaboration with Pendopharm. I welcome David to the board and look forward to the expertise and insight he brings. We believe CyCol has significant potential to treat unmet clinical needs in ulcerative colitis and that Pendopharm, through its existing and growing franchise in the GI therapeutic area, is strongly positioned to maximise the potential of our lead product in Canada. We are confident that this licence agreement will be the first of a number of important strategic collaborations to be announced in relation not only to CyCol, but also to the broadly-applicable SmPill drug delivery technology”

Dr David Goodman, CEO of Pharmascience Inc. added: “We are very pleased to be working with Sigmoid to bring CyCol to Canada. CyCol is a strategic fit with our GI franchise, and brings another innovative product to the Pendopharm portfolio with attractive therapeutic benefits for patients.”